Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [31] Guselkumab for the treatment of adults with moderate to severe plaque psoriasis
    Puig, Lluis
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (06) : 589 - 597
  • [32] Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis
    Feldman, Steven R.
    Zhao, Yang
    Shi, Lizheng
    Tran, Mary Helen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (10) : 874 - 888
  • [33] Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
    Girolomoni, Giampiero
    Savage, Laura
    Gisondi, Paolo
    Svensson, Ake
    Mahe, Emmanuel
    Augustin, Matthias
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2023, 13 (10) : 2171 - 2185
  • [34] Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
    Andrea Messori
    Sabrina Trippoli
    Drugs - Real World Outcomes, 2015, 2 (3) : 319 - 321
  • [35] Switching of biologics in psoriasis: Reasons and results
    Honda, Hiromi
    Umezawa, Yoshinori
    Kikuchi, Sota
    Yanaba, Koichi
    Fukuchi, Osamu
    Ito, Toshihiro
    Nobeyama, Yoshimasa
    Asahina, Akihiko
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2017, 44 (09) : 1015 - 1019
  • [36] Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey
    Armstrong, April W.
    Jayade, Sayeli
    Rege, Sanika
    Joshi, Namita
    Patel, Vardhaman
    Kalirai, Samaneh
    Wolin, Daniel
    Boyle, Kimberly
    Patel, Dipen
    Seigel, Lauren
    DERMATOLOGY AND THERAPY, 2024, 14 (02) : 421 - 439
  • [37] Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
    Loft, Nikolai Dyrberg
    Egeberg, Alexander
    Rasmussen, Mads Kirchheiner
    Bryld, Lars Erik
    Gniadecki, Robert
    Dam, Tomas Norman
    Iversen, Lars
    Skov, Lone
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (13) : 1224 - 1230
  • [38] Managing Moderate-to-Severe Psoriasis in the Elderly
    Nicola Balato
    Cataldo Patruno
    Maddalena Napolitano
    Angela Patrì
    Fabio Ayala
    Raffaele Scarpa
    Drugs & Aging, 2014, 31 : 233 - 238
  • [39] Biologic Therapies for Moderate to Severe Psoriasis Are Not Interchangeable
    Puig, L.
    ACTAS DERMO-SIFILIOGRAFICAS, 2014, 105 (05): : 483 - 486
  • [40] Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey
    April W. Armstrong
    Sayeli Jayade
    Sanika Rege
    Namita Joshi
    Vardhaman Patel
    Samaneh Kalirai
    Daniel Wolin
    Kimberly Boyle
    Dipen Patel
    Lauren Seigel
    Dermatology and Therapy, 2024, 14 : 421 - 439